VALANX Biotech Appoints New Chief Scientific Officer
VALANX Biotech, a biotech company, has appointed Klaus Orlinger, PhD, as its new Chief Scientific Officer.
Klaus brings over 15 years of industry experience in developing oncology and infectious disease drug candidates.
He will drive the Company's scientific strategy, including development of its flagship protein conjugation platform, GoldenSite™.
This appointment bolsters the company's leadership team as it progresses its first antibody drug conjugate to candidate selection phase.
Author's summary: VALANX Biotech appoints Klaus Orlinger as CSO.